{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:45Z","timestamp":1787020725543,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82570246"],"award-info":[{"award-number":["82570246"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82530008"],"award-info":[{"award-number":["82530008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2026ZD055390"],"award-info":[{"award-number":["2026ZD055390"]}]},{"name":"Shanghai Lymphoma Clinical Cohort of Shanghai Hospital Development Center","award":["SHDC2025CCS008"],"award-info":[{"award-number":["SHDC2025CCS008"]}]},{"name":"Shanghai Clinical Research Center for Cell Therapy","award":["23J41900100"],"award-info":[{"award-number":["23J41900100"]}]},{"name":"Collaborative Innovation Center of Systems Biomedicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01796-5","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:04:52Z","timestamp":1780049092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies"],"prefix":"10.1186","volume":"19","author":[{"given":"Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Roerker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1796_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"1796_CR2","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, et al. NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw. 2023;21:1118\u201331.","journal-title":"J Natl Compr Canc Netw"},{"key":"1796_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01018-6","volume":"14","author":"M Lumish","year":"2021","unstructured":"Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol. 2021;14:5.","journal-title":"J Hematol Oncol"},{"key":"1796_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402:142\u201358.","journal-title":"Lancet"},{"key":"1796_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141:467\u201380.","journal-title":"Blood"},{"key":"1796_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J. 2024;14:27.","journal-title":"Blood Cancer J"},{"key":"1796_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","volume":"25","author":"Z Mahmoudjafari","year":"2019","unstructured":"Mahmoudjafari Z, Hawks KG, Hsieh AA, Plesca D, Gatwood KS, Culos KA. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group survey on chimeric antigen receptor T cell therapy administrative, logistic, and toxicity management practices in the United States. Biol Blood Marrow Transplant. 2019;25:26\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1796_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jha2.335","volume":"3","author":"ST Bhaskar","year":"2022","unstructured":"Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022;3:39\u201345.","journal-title":"EJHaem"},{"key":"1796_CR9","doi-asserted-by":"publisher","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","volume":"9","author":"GD Myers","year":"2021","unstructured":"Myers GD, Verneris MR, Goy A, Maziarz RT. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia. J Immunother Cancer. 2021;9:e002056.","journal-title":"J Immunother Cancer"},{"key":"1796_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01097-z","volume":"14","author":"Y Chu","year":"2021","unstructured":"Chu Y, Zhou X, Wang X. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. J Hematol Oncol. 2021;14:88.","journal-title":"J Hematol Oncol"},{"key":"1796_CR11","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105:1494\u2013506.","journal-title":"Haematologica"},{"key":"1796_CR12","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","volume":"19","author":"S Barrena","year":"2005","unstructured":"Barrena S, Almeida J, Yunta M, L\u00f3pez A, Fern\u00e1ndez-Mosteir\u00edn N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia. 2005;19:1376\u201383.","journal-title":"Leukemia"},{"key":"1796_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00418-015-1326-2","volume":"144","author":"CM de Winde","year":"2015","unstructured":"de Winde CM, Zuidscherwoude M, Vasaturo A, van der Schaaf A, Figdor CG, van Spriel AB. Multispectral imaging reveals the tissue distribution of tetraspanins in human lymphoid organs. Histochem Cell Biol. 2015;144:133\u201346.","journal-title":"Histochem Cell Biol"},{"key":"1796_CR14","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/blood-2016-11-748137","volume":"128","author":"F Bertoni","year":"2016","unstructured":"Bertoni F, Stathis A. Staining the target: CD37 expression in lymphomas. Blood. 2016;128:3022\u20133.","journal-title":"Blood"},{"key":"1796_CR15","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.4049\/jimmunol.172.5.2953","volume":"172","author":"AB van Spriel","year":"2004","unstructured":"van Spriel AB, Puls KL, Sofi M, Pouniotis D, Hochrein H, Orinska Z, et al. A regulatory role for CD37 in T cell proliferation. J Immunol. 2004;172:2953\u201361.","journal-title":"J Immunol"},{"key":"1796_CR16","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1128\/MCB.20.15.5363-5369.2000","volume":"20","author":"KP Knobeloch","year":"2000","unstructured":"Knobeloch KP, Wright MD, Ochsenbein AF, Liesenfeld O, L\u00f6hler J, Zinkernagel RM, et al. Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol. 2000;20:5363\u20139.","journal-title":"Mol Cell Biol"},{"key":"1796_CR17","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21:694\u2013708.","journal-title":"Cancer Cell"},{"key":"1796_CR18","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.4049\/jimmunol.1402414","volume":"195","author":"JL Wee","year":"2015","unstructured":"Wee JL, Schulze KE, Jones EL, Yeung L, Cheng Q, Pereira CF, et al. Tetraspanin CD37 regulates \u03b22 Integrin-mediated adhesion and migration in neutrophils. J Immunol. 2015;195:5770\u20139.","journal-title":"J Immunol"},{"key":"1796_CR19","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3324\/haematol.2018.207266","volume":"104","author":"SC Oostindie","year":"2019","unstructured":"Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, et al. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica. 2019;104:1841\u201352.","journal-title":"Haematologica"},{"key":"1796_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2362454","volume":"13","author":"M Bobrowicz","year":"2024","unstructured":"Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, et al. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies. Oncoimmunology. 2024;13:2362454.","journal-title":"Oncoimmunology"},{"key":"1796_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-020-0292-7","volume":"10","author":"SC Oostindie","year":"2020","unstructured":"Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, et al. DuoHexaBody-CD37(\u00ae), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer J. 2020;10:30.","journal-title":"Blood Cancer J"},{"key":"1796_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-2902","volume":"82","author":"P Algate","year":"2022","unstructured":"Algate P, Liu Z, Yuan S, Liu H, Domeier C, Jiang H, et al. Abstract 2902: Development of PSB202, a bifunctional antibody pair that target CD20 and CD37, for the treatment of B-cell malignancies. Cancer Res. 2022;82:2902.","journal-title":"Cancer Res"},{"key":"1796_CR23","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"1796_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289\u201396.","journal-title":"Nat Methods"},{"key":"1796_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/cac2.12429","volume":"43","author":"S Ding","year":"2023","unstructured":"Ding S, Qiao N, Zhu Q, Tong Y, Wang S, Chen X, et al. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer. Cancer Commun. 2023;43:661\u201384.","journal-title":"Cancer Commun"},{"key":"1796_CR26","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396\u2013401.","journal-title":"Science"},{"key":"1796_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"1796_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41592-024-02243-4","volume":"21","author":"SE Irac","year":"2024","unstructured":"Irac SE, Soon MSF, Borcherding N, Tuong ZK. Single-cell immune repertoire analysis. Nat Methods. 2024;21:777\u201392.","journal-title":"Nat Methods"},{"key":"1796_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110713","volume":"39","author":"X Ye","year":"2022","unstructured":"Ye X, Wang L, Nie M, Wang Y, Dong S, Ren W, et al. A single-cell atlas of diffuse large B cell lymphoma. Cell Rep. 2022;39:110713.","journal-title":"Cell Rep"},{"key":"1796_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474.","journal-title":"Science"},{"key":"1796_CR31","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1007\/s10637-020-00916-3","volume":"38","author":"F Kroschinsky","year":"2020","unstructured":"Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, et al. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Invest New Drugs. 2020;38:1472\u201382.","journal-title":"Invest New Drugs"},{"key":"1796_CR32","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10637-014-0125-2","volume":"32","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, et al. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR\u2122 therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs. 2014;32:1213\u201325.","journal-title":"Invest New Drugs"},{"key":"1796_CR33","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, et al. Glofitamab, a novel, bivalent CD20-targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: A phase I trial. J Clin Oncol. 2021;39:1959\u201370.","journal-title":"J Clin Oncol"},{"key":"1796_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3324\/haematol.2015.139493","volume":"101","author":"NH Fowler","year":"2016","unstructured":"Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, et al. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016;101:531\u201340.","journal-title":"Haematologica"},{"key":"1796_CR35","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with Rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885\u201393.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01796-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01796-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01796-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:50:12Z","timestamp":1780473012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01796-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01796-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was done in accordance with the principles of the Declaration of Helsinki, the international standards of good clinical practice, and applicable local laws and regulations. The study protocol and all amendments were reviewed and approved by the institutional review board or independent ethics committee at each participating site. All patients provided written informed consent before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Li Wang, Jiaying Liu, Keshu Zhou, Zengjun Li, Yun Zeng, Ying Qian, Yuping Sun, Hui Wu, Lindsay Roerker, Peter Tan, and Wei-Li Zhao declare that they have no conflict of interest. Chen Ma, Liwei Zhou, Xianlin Duan, and Xiaoyan Kang are full-time employees of Qilu Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}